neurotechnology accelerator

“At NTI, our mission is to restore quality of life to those suffering from neurological diseases, such as dementia, epilepsy and addiction. Through our innovations, we will ensure that patients benefit from new treatments as quickly as possible,” Lucas said.

Neurological disorders affect 1 in 6 individuals worldwide

However, the human element remains crucial, with AI serving as an assistant rather than a replacement. As we venture into new frontiers of research and innovation, we must also consider the ethical, legal, and social implications of integrating machines into various processes.

At Battelle, our close work with regulators can help provide ground truth for these technologies, potentially aiding in the development of thoughtful regulations that make a difference.

This is a prime example of human-machine collaboration, and it sets a precedent for other application areas.

When it comes to neurotechnology, we must loop in AI and algorithms to process the massive amount of data generated by the patient’s neurons. Since everyone’s neurons are different, interpreting the intent of these signals is a difficult task.

While this concept may seem too futuristic for regulatory bodies to fully comprehend today, work is already underway in this direction. We are contemplating these types of innovations, and I see immense potential and a promising future for such advancements.

AI has the potential to completely revolutionize patient care and personalized medicine.

his is where our experts at Battelle come in, with laboratories and specialized equipment to verify these predictions.

The AI then generates variants of these molecules that might not have been considered intuitively, unveiling new potential molecule combinations with unique properties.

However, human expertise remains crucial in assembling prototypes, testing, verifying the design, and making necessary revisions

An AI system knowledgeable in fluid mechanics and engineering principles such as stress, strain, and friction could propose innovative designs or new component combinations that may not have been considered by humans.

AI will have a significant impact on drug discovery and delivery.

it is based on the corpus of all previously generated human works.

Humans are already relying on AI to lighten the load of many day-to-day tasks.

AI will still be viewed as an assistant.

Create a Pilot Network of Three Nodes

To achieve these goals, the policy Plan of Action includes the following steps:

to initiate the BioNETWORK and use its structure to fulfill economic goals and create industrial growth opportunities within its three themes:

The BioNETWORK acts as the physical and information layer of manufacturing innovation, generating market forces, and leveraging ubiquitous data capture and feedback loops to accelerate innovation and scale-up necessary for full-scale production of novel biomaterials, polymers, small molecules, or microbes themselves. As a secure network, BioNETWORK serves as the physical and virtual backbone of the constituent biomanufacturing entities and their customers, providing unified, distributed manufacturing facilities, digital infrastructure to securely and efficiently exchange information/datasets, and enabling automated process development. Together the nodes function in an integrated way to adaptively solve biotechnology infrastructure challenges as well as load balancing supply chain constraints in real-time depending on the need. This includes automated infrastructure provisioning of small, medium, or large biomanufacturing facilities, supply of regional raw materials, customization of process flow across the network, allocation of labor, and optimization of the economic effectiveness. The BioNETWORK also supports the implementation of a national, multi-tenant cloud lab and enables a systematic assessment of supply chain capabilities/vulnerabilities for biomanufacturing.

CHIPS and Science Act.

The BioNETWORK inverts the problem of a traditional centralized biomanufacturing facility and expertise paradigm by delivering a decentralized, resilient network enabling members to rapidly access manufacturing facilities, expertise, and data repositories, as needed and wherever they reside within the system, by integrating the substantial existing U.S. bioindustrial capabilities and resources to maximize nationwide outcomes.

The future of United States industrial growth resides in the establishment of biotechnology as a new pillar of industrial domestic manufacturing, thus enabling delivery of robust supply chains and revolutionary products such as materials, pharmaceuticals, food, energy.

Reliant on a narrow set of feedstocks and reagents that are not local, introducing supply chain vulnerabilities that can halt bioproduction in its earliest steps of manufacturing. Inflexible for determining the most effective, stable, scalable, and safe methods of biomanufacturing needed for multiple products in large facilities. Serial in scheduling, which introduces large delays in production and limits capacity and product diversity.  Bespoke and not easily replicated when it comes to selection and design of microbial strains, cell free systems, and sequences of known function outside of the facility that made them. Scale-up and reproducibility of biomanufacturing products are limited. Creating waste streams because circular economies are not leveraged. Vulnerable to personnel shortages due to shifting economic, health, or other circumstances related to undertraining of a biotechnology specialized workforce.